Author: OurCrowd

[Biolojic in GlobeNewswire] Biolojic Design earns preclinical milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)

Mar 25, 2026 |

WASHINGTON and NESS ZIONA, Israel, March 25, 2026 (GLOBE NEWSWIRE) — Biolojic Design, a biotechnology company that uses AI to transform antibodies into multifunctional, programmable medicines, today announced it has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd. (Teva), as TEV ‘325 (formerly BD9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP), has achieved a preclinical milestone. Teva has an exclusive license to develop and commercialize TEV ‘325 for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis.  Read...

Read More

[Cyabra in Globe Newswire] Cyabra and Orchestra partner to deliver real-time brand safety at scale

Mar 25, 2026 |

New York, NY, March 25, 2026 (GLOBE NEWSWIRE) –Cyabra Strategy Ltd. (“Cyabra”), the solution that analyzes actors, behaviors, and content to uncover coordinated digital manipulation, and Orchestra, a strategic marketing and communications firm, today announced a strategic partnership. The collaboration brings real-time narrative protection, crisis monitoring, and AI-driven brand safety to Orchestra clients worldwide. Read more...

Read More